Contents:

TABLE OF CONTENTS 1. Overview of the Epigenetics Market and R&D 1.1 Overview of Epigenetics for R&D, Diagnostics & Therapeutics 1.1.2 Definition and Brief History of Epigenetics 1.1.3 Epigenetic Mechanisms in Human Health 1.1.4 Cancers, Neuropsychological Conditions or Other Diseases and Demographics Involving Epigenetics 1.1.5 Tools, Technologies, Equipment & Products for Epigenetic R&D 1.1.6 Diagnostics for Epigenetic Conditions 1.1.7 Therapeutics for Epigenetic Diseases 1.2 Epigenetics Applications 1.2.1 Academic Life Science Research Applications 1.2.2 Clinical Diagnostic Applications 1.2.3 Pharma/ Biotech Therapeutic Applications 2. Major Alliances, M&As and IP 2.1 Summary of Key Alliances and M&As Involving Epigenetics 2.1.1 Definitions of Alliance and M&A Deal Types 2.1.2 Highlights of Major Alliances and M&As Involving Epigenetics 2.1.3 Data Tables for Alliances and M&As, 2005 – Oct. 2008 2.2 Patents, Business Development and Challenges 2.2.1 Highlights of Companies That Own IP Involving Epigenetic Techs. 2.2.2 The Business Value of Epigenetic Technologies and Products 2.2.3 Business Development Challenges 2.2.4 Patent Challenges 3.3 The Market and Outlook for the Epigenetics Industry 3.1 The Total Epigenetics Market Size, 2008~2013 3.2 Epigenetic Market by Product Segments 3.2.2 Epigenetic Life Science R&D Tools and Technologies Segment and Sub-segments 3.2.3 Epigenetic Diagnostics Segment and Sub-segments 3.2.4 Epigenetic Therapeutics Segment and Sub-segments 3.2.5 WW Epigenetic Market By Product Segment Shares, 2008 & 2013 3.3 Market by Leading Diseases 3.3.2 Cancer Disease Segment 3.3.3 Neuro-psychological (CNS) Segment 3.3.4 Infections Disease Segment 3.3.5 Respiratory Disease Segment 3.3.6 Reproductive Disease Segment 3.3.7 Others Disease Segment 3.4 Epigenetic Market by R&D Developer Segments 3.4.2 Academic/Gov. Basic Life Science Developer Sub-segments 3.4.3 Diagnostics Developer Sub-segments 3.4.4 Pharma/ Biotech Rx/Tx Developers Sub-segments 3.5 Market by WW Regions 3.5.2 North America 3.5.3 Europe 3.5.4 Japan 3.5.5 ROW 4. Activities of Epigenetic Product Developers 4.1 Epigenetic Diagnostics Developers 4.1.1~ 4.1.5 Total 5 companies 4.2 Equipment Systems Companies 4.2.1~ 4.2.5 Total 5 companies 4.3 Consumables, Reagents and Kits Companies 4.3.1~ 4.3.10 Total 10 companies 4.4 Contract R&D Services Companies 4.4.1~ 4.4.7 Total 7 companies 4.5 Life Science Software Companies 4.5.1~ 4.5.5 Total 5 companies 5. Conclusions and New Business Opportunities 5.1 The Future of the Epigenetics Market 5.1.1 Tools & Technologies for Genomewide Epigenetic R&D 5.1.1.1 Commercial DNA Microarrays, ChIP on Chip and Methylation 5.1.1.2 High-Throughput Sequencing and ChIP-Seq. 5.1.1.3 Other Front Runner Technologies 5.1.2 Consumables & Reagent Kits 5.1.3 Commercial Diagnostic/ Test Services 5.1.4 Therapeutics Involving Epigentics 5.2 Likely Epigenetics Success and Failure Factors 5.2.1 US Initiative - The NIH Roadmap Epigenomics Program Initiatives 5.2.2 European Union Initiative - The European Union Epigenetics Initiative 5.2.3 Key M&As Have Enabled Epigenetic Product Companies 5.2.4 Commercial Epigenetic Diagnostics Have Reached the Market With More to Come 5.2.5 Commercial Epigenetic Therapeutics Have Reached the Market 5.3 Epigenetic Business Opportunities or Commercial Implications 5.3.1 New Business Opportunities for American and European Companies 5.3.1.1 Life Science Tools and Technologies 5.3.1.2 Explore Other WW Regions for Cost Savings or New Customers 5.3.1.3 Enter Asia for Business Opportunities 5.3.2 New Business Opportunities for Japanese and Asian Companies 6. Appendix 6.1 Glossary of Epigenetics 6.2 Company Contacts 6.3 Grant Recipients and Epigenomic Projects LIST OF TABLES Table 1. Demographics of Epigenetic Related Diseases Table 2. Summary of Key Alliances and M&As, 2005 to Oct.- 2008 Table 3. Major Alliances and M&As Jan. to Oct. 2008 Table 4. Major Alliances and M&As - 2007 Table 5. Major Alliances and M&As - 2006 Table 6. Major Alliances and M&As - 2005 Table 7. Epigenetics Related US Patents Issued to Orgs., 2007 to Oct.- 2008 Table 8. Valuations of Major M&As Involving Epigenetics. Table 9. Total WW Epigenetic Product Market Revenues, 2008-2013 Table 10. WW Epigenetic Market By Vendor Product Segments $M Table 11. Epigenetic Life Science R&D Tools & Technologies Sub-segments $M Table 12. Epigenetic Diagnostics Sub-segments $M Table 13. Epigenetic Therapeutics Sub-segments $M Table 14. WW Epigenetic Market By Vendor Product Shares %, 2008 & 2013 Table 15. WW Epigenetic Market By Leading Diseases $M Table 16. Major Cancer Types Targeted in R&D and Shares Table 17. WW Epigenetic Market By Developers $M Table 18. Academic/Gov. Basic Life Science R&D $M Table 19. Diagnostics Developers Table 20. Pharma/ Biotech Rx/Tx Developers Table 21. WW Epigenetic Market By Regions $M Table 22. High-Density Whole Genome Microarrays for Epigenetics Table 23. High-Throughput DNA Sequencing For Epigenetics Table 24. Other Technologies for Epigenetics Table 25. Epigenetic Diagnostics Development Pipeline Table 26. Therapeutics in Clinical Pipeline Involving Epigenetics Table 27. NIH Roadmap Epigenomics Program Initiatives Table 28. Glossary of Epigenetic Terms Table 29. List of Company Contacts Table 30. Selected NIH Grant Recipients and Epigenomic Projects LIST OF FIGURES Figure 1. The Epigenetic Product Market Ecosystem Figure 2. Highlights of Epigenetic Mechanisms Figure 3. Increasing Number of PubMed Articles Regarding Epigenetics Figure 4. Total WW Epigenetic Product Market Revenues, 2008-2013 Figure 5. WW Epigenetic Market By Vendor Products $M Figure 6. WW Epigenetic Market By Vendor Product Shares %, 2008 & 2013 Figure 7. WW Epigenetic Market By Leading Diseases $M Figure 8. WW Epigenetic Market By Developers $M Figure 9. WW Epigenetic Market By Regions $M